Treatment of head and neck cancer: The role of chemotherapy

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 2, 1996, Pages 97-116

  Adelstein, David J ^a   Tan, Eng Huat ^b   Lavertu, Pierre ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINCRISTINE; VINDESINE;

HEAD AND NECK CANCER; HUMAN; METASTASIS; NASOPHARYNX CANCER; REVIEW;

EID: 0030270211     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00215-6     Document Type: Review

References (215)

1. [1] Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 21:281-288, 1994.
2. [2] Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 328:184-194, 1993.
3. [3] Decker J, Goldstein JC. Current concepts in otolaryngology -Risk factors in head and neck cancer. N Engl J Med 306:1151-1155, 1982.
4. [4] Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85:95-111, 1993.
5. [5] Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 40:145-151, 1977.
6. [6] Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21:382-397, 1994.
7. [7] Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: Role of tobacco and alcohol. J Natl Cancer Inst 86:131-137, 1994.
8. [8] Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer 74:1933-1938, 1994.
9. [9] Adelstein DJ. The community approach to salvage therapy for advanced head and neck cancer. Semin Oncol 21 (Suppl 7): 52-57, 1994.
10. [10] Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol/Oncol Clin N Am 5:667-686, 1991.
11. [11] DeConti RC, Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 48:1061-1072, 1981.
12. [12] Veronesi A, Zagonel V, Tirelli U, et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study. J Clin Oncol 3:1105-1108, 1985.
13. [13] Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52:206-210, 1983.
14. [14] Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: A Southwest Oncology Group Study. Cancer Treat Rep 69:577-581, 1985.
15. [15] Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 21:311-319, 1994.
16. [16] Vogl SE, Schoenfeld DA, Kaplan BH, Lerner HJ, Engstrom PF, Horton J. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56:432-442, 1985.
17. [17] The Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311-315, 1990.
18. [18] Forastiere AA, Metch B, Schuller DE. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexale in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 10:1245-1251, 1992.
19. [19] Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992.
20. [20] Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53:1819-1824, 1984.
21. [21] Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740-2744, 1985.
22. [22] Rowland KM, Taylor SG, Spiers ASD, et al. Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 70:461-464, 1986.
23. [23] Mercier RJ, Neal GD, Mattox DE, Gates GA, Pomeroy TC, Von Hoff DD. Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 60:2609-2612, 1987.
24. [24] Vokes EE, Choi KE, Schilsky RE, et al. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618-626, 1988.
25. [25] Cascinu S, Fedeli A, Fedeli SL, Catalano G. Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. Br J Cancer 69:392-393, 1994.
26. [26] Arquette MA, Mortimer JE, Loehrer PJ, Mandanas RA. A phase II Hoosier Oncology Group trial of interferon alpha-2b (IFN) added to cisplatin (CDDP) and 5-fluorouracil (FU) in recurrent or metastatic head and neck cancer. Proc ASCO 13:280, 1994 (Abstr).
27. [27] Shirinian M, Choksi AJ, Dimery I, et al. Phase I/II study of cisplatin (P) + 5-fluorouracil (F) + α-interferon (IFN) for recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc ASCO 11:249, 1992 (Abstr).
28. [28] Hussain M, Benedetti J, Smith R, Schuller D, Ensley J. Alpha interferon (αIFN) + 5-fluorouracil (5-FU) + cisplatin (CDDP) in advanced squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group (SWOG) phase II trial. Proc ASCO 13:279, 1994 (Abstr).
29. [29] Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21 (Suppl 8):49-52, 1994.
30. [30] Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 71:2326-2331, 1993.
31. [31] Randolph VL, Vallejo A, Spiro RH, et al. Combination therapy of advanced head and neck cancer. Induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 41:460-467, 1978.
32. [32] Brown AW, Blom J, Butler WM, Garcia-Guerrero G, Richardson MF, Henderson RL. Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 45:2830-2835, 1980.
33. [33] Jacobs C. Adjuvant and neoadjuvant treatment of head and neck cancers. Semin Oncol 18:504-514, 1991.
34. [34] Stupp R, Weichselbaum RR, Yokes EE. Combined modality therapy of head and neck cancer. Semin Oncol 21:349-358, 1994.
35. 0 disease. Semin Oncol 16 (Suppl 6):44-57, 1989.
36. [36] Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: Most effective agents, areas of promise. Oncology 3:79-88, 1989.
37. [37] Decker DA, Drelichman A, Jacobs J. et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 51:1353-1355, 1983.
38. [38] Cognetti F, Pinnaro P, Carlini P, et al. Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. Cancer 62:251-261. 1988.
39. 0) squamous cancer of the head and neck. Cancer 50:840-844. 1982.
40. [40] Ervin TJ, Clark JR, Weichselbaum RR, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 5:10-20, 1987.
41. [41] Hill BT, Price LA. The role of adjuvant chemotherapy in the treatment of advanced head and neck cancer. Acta Oncol 29:695-703, 1990.
42. [42] Al-Sarraf M, Kish JA, Ensley JF. The Wayne State University experience with adjuvant chemotherapy of head and neck cancer. Hematol/Oncol Clin N Am 5:687-700, 1991.
43. [43] Yokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 8:241-247, 1990.
44. [44] Dreyfuss AI, Clark JR, Wright JE, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann hit Med 112:167-172, 1990.
45. [45] Pfister DG, Bajorin D, Motzer R, et al. Cisplatin, fluouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 120:89-95, 1994.
46. [46] Vokes EE, Haraf DJ, McEvilly JM, et al. Neoadjuvant PEL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach. Ann Oncol 3:79-81, 1992.
47. [47] Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-h 5-FU infusion and cisplatin. Cancer 55:1123-1128, 1985.
48. [48] Clark JR, Fallon BG, Dreyfuss AI, et al. Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. Semin Oncol 15 (Suppl 3):35-44, 1988.
49. [49] Posner MR, Weichselbaum RR, Fitzgerald TJ, et al. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously-untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 11:1887-93, 1985.
50. [50] Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811-814, 1984.
51. [51] Cognetti F, Pinnarò P, Ruggeri EM, et al. Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 7:829-837, 1989.
52. [52] Tannock IF, Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol 4:1121-1126, 1986.
53. [53] Ensley JF, Maciorowski Z. Clinical applications of DNA content parameters in patients with squamous cell carcinomas of the head and neck. Semin Oncol 21:330-339, 1994.
54. [54] Al-Sarraf M. Head and neck cancer: Chemotherapy concepts. Semin Oncol 15:70-85, 1988.
55. [55] Fazekas JT, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Int J Radiat Oncol Biol Phys 6:533-541, 1980.
56. [56] Petrovich Z, Block J, Kuisk H, et al. A randomized comparison of radiotherapy with a radiotherapy-chemotherapy combination in stage IV carcinoma of the head and neck. Cancer 47:2259-2264, 1981.
57. [57] Stell PM, Dalby JE, Strickland P, Fraser JG, Bradley PJ, Flood LM. Sequential chemotherapy and radiotherapy in advanced head and neck cancer. Clin Radiol 34:463-467, 1983.
58. [58] Siodlak MZ, Dalby JE, Bradley PJ, et al. Induction VBM plus radiotherapy, versus radiotherapy alone for advanced head and neck cancer: long-term results. Clin Otolaryngol 14:17-22, 1989.
59. [59] Shetty P, Mehta A, Shinde S, Mazumdar, Hingorani C. Controlled study in squamous cell carcinoma of base of tongue using conventional radiation, radiation with single drug and radiation with multiple drug chemotherapy. Proc ASCO 4:152, 1985 (Abstr).
60. [60] Taylor SG, Applebaum E, Showel JL, et al. A randomized trial of adjuvant chemotherapy in head and neck cancer. J Clin Oncol 3:672-679, 1985.
61. [61] Kun LE, Toohill RJ, Holoye PY, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 12:173-178, 1986.
62. [62] Szpirglas H, Nizri D, Marneur M, Lacoste JP, Benslama L. Neo-adjuvant chemotherapy. A randomized trial before radiotherapy in oral and oro-pharyngeal carcinomas: end results. Head and Neck Oncology Research. Proc 2nd Int Head and Neck Oncology Research Conference, Arlington, VA, USA, 10-12 September 1987, Kugler Publications, Amsterdam, 261-264.
63. [63] Rentschler RE, Wilbur DW, Petti GH, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - a prospective, randomized study. J Clin Oncol 5:278-285, 1987.
64. [64] Toohill RJ, Anderson T, Byhardt RW, et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. Arch Otolaryngol Head Neck Surg 113:758-761, 1987.
65. [65] Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer 60:301-311, 1987.
66. [66] Schuller DE, Metch B, Mattox D, Stein DW, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98:1205-1211, 1988.
67. [67] Carugati A, Pradier R, de la Torre A. Combination chemotherapy (CT) pre radical treatment for head and neck squamous cell carcinoma (SCC). Proc ASCO 7:152, 1988 (Abstr).
68. [68] Martin M, Hazan A, Vergnes L, et al. Randomized study of 5-fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: A preliminary report. Int J Radiat Oncol Biol Phys 19:973-975, 1990.
69. [69] Jortay A, Demard F, Dalesio O, et al. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years. Acta Chir Belg 90:115-122, 1990.
70. [70] Richard JM, Kramer A, Molinari R, et al. Randomized EORTC Head and Neck Cooperative Group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer 27:821-827, 1991.
71. [71] Wolf GT, Hong WK, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-90, 1991.
72. [72] Mazeron JJ, Martin M, Brun B, et al. Induction chemotherapy in head and neck cancer: Results of a phase III trial. Head and Neck 14:85-91, 1992.
73. [73] Jaulerry C, Rodriguez J, Brunin F, et al. Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials. Int J Radiat Oncol Biol Phys 23:483-489, 1992.
74. [74] Depondt J, Gehanno P, Martin M, et al. Neoadjuvant chemotherapy with carboplatin/5-nuorouracil in head and neck cancer. Oncology 50 (suppl 2):23-27, 1993.
75. [75] DiBlasio B, Barbieri W, Bozzetti A, Iotti C, DiSarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: Loco-regional treatment with and without neoadjuvant chemotherapy. Proc ASCO 13:279, 1994 (Abstr).
76. [76] Hasegawa Y, Matsuura H, Fukushima M, Kano M, Shimozato K. A randomized trial of neoadjuvant chemotherapy with cisplatin and 5-FU in advanced head and neck cancer. Proc ASCO 13:286, 1994 (Abstr).
77. [77] Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994.
78. [78] Stell PM, Rawson NSB. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 61:779-787, 1990.
79. [79] Johnson JT, Myers EN, Schramm VL, et al. Adjuvant chemotherapy for high-risk squamous cell carcinoma of the head and neck. J Clin Oncol 5:456-458, 1987.
80. [80] Laramore GE, Scott CB, Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 23:705-713, 1992.
81. [81] Horiuchi M, Inuyama Y, Miyake H. Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: A prospective randomized study. Proc ASCO 13:284, 1994 (Abstr).
82. [82] Domenge C, Marandas P, Vignoud J, et al. Post-surgical adjuvant chemotherapy in extracapsular spread invaded lymph node (N + R + ) of epidermoid carcinoma of the head and neck. A randomized multicentric trial. Proc 2nd Int Conf Head and Neck Cancer. July 31-August 5, 1988, Boston, Mass (Abstr).
83. [83] Looney WB, Hopkins HA. Rationale for different chemotherapeutic and radiation therapy strategies in cancer management. Cancer 67:1471-1483, 1991.
84. [84] Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979.
85. [85] Merlano M, Rosso R, Sertoli MR, et al. Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: A phase III study. J Clin Oncol 6:627-632, 1988.
86. [86] Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. Cancer 67:915-921, 1991.
87. [87] Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327:1115-21, 1992.
88. [88] Adelstein DJ, Saxton JP, Van Kirk MA, et al. Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer. Am J Clin Oncol 17:369-373, 1994.
89. [89] Lo TCM, Wiley AL, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study. Am J Roentgenol 126:229-235, 1976.
90. [90] Sanchiz F, Milla A, Torner J, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347-1350, 1990.
91. [91] Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluoro uracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653, 1994.
92. [92] Byfield JE, Sharp TR, Frankel SS, Tang SG, Callipari FB. Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 2:406-413, 1984.
93. [93] Weppelmann B, Wheeler RH, Peters GE, et al. A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 20:357-360, 1991.
94. [94] Gupta NK, Pointon RCS, Wilkinson PM. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Rad 38:575-581, 1987.
95. [95] Shanta V, Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol 31:617-620, 1980.
96. [96] Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial. J Clin Oncol 5:1410-1418, 1987.
97. [97] Vermund H, Kaalhus O, Winther F, Trausjo J, Thorud E, Harang R. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys 11:1877-1886, 1985.
98. [98] Eschwege F, Sancho-Garnier H, Gerard J.P., et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: Experience of the European Organization for Research and Treatment of Cancer. NCI Monogr 6:275-278, 1988.
99. [99] Weissberg JB, Son YH, Papac RJ, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17:3-9, 1989.
100. [100] Stefani S, Chung TS. Hydroxyurea and radiotherapy in head and neck cancer-long term results of a double blind randomized prospective study. Int J Radiat Oncol Biol Phys 6:1398, 1980 (Abstr).
101. [101] Wheeler R, Salter M, Stephens S, et al. Simultaneous therapy with high-dose cisplatin and radiation for unresectable squamous cell cancer of the head and neck: A phase I-II study. NCI Monogr 6:339-341, 1988.
102. [102] Slotman GJ, Doolittle CH, Glicksman AS. Preoperative combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Cancer 69:2736-2743, 1992.
103. [103] Hasetow RE, Adams GS, Oken MM, Goudsmit A, Lerner HJ, Marsh JC. Cis-platinum (DDP) with radiation therapy (RT) for locally advanced unresectable head and neck cancer. Proc ASCO 2:160, 1983 (Abstr).
104. [104] Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer 66:1861-1868, 1990.
105. [105] Haselow RE, Warshaw MG, Oken MM, et al. Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. Head and Neck Cancer 2:279-281, 1990.
106. [106] Volling P, Staar S, Achterrath W, Müller RP. Carboplatin plus radiation therapy in head and neck cancer. Semin Oncol 18 (Suppl 2): 17-22, 1991.
107. [107] Eisenberger M, Jacobs M. Simultaneous treatment with single-agent chemotherapy and radiation for locally advanced cancer of the head and neck. Semin Oncol 19 (Suppl 11):41-46, 1992.
108. [108] Stupp R, Haraf D, Malone D, Moran W, Weichselbaum RR, Yokes EE. Continuous infusion (C.I.) paclitaxel (TAX), C.I. 5-fluorouracil, oral hydroxyurea and concomitant radiotherapy (RT) for the treatment of head and neck cancer (HNC). Head and Neck 16:491, 1994 (Abstr).
109. [109] Haffty BG, Son YH, Sasaki CT, et al. Mitomycin-C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 27:241-250, 1993.
110. [110] Bachaud JM, David JM, Boussin G, Day N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 20:243-246, 1991.
111. [111] Parsons JT, Bova FJ, Million RR. A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 6:1645-1652, 1980.
112. [112] Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20:13-20, 1991.
113. [113] Taylor SG, Murthy AK, Caldarelli DD, et al. Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J Clin Oncol 7:846-856, 1989.
114. [114] Adelstein DJ, Sharan VM, Earle AS, et al. Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol 13:440-447, 1990.
115. [115] Schmotzer JA, Adelstein DJ. Long-term survival after simultaneous chemoradiotherapy (CRT) for locally confined squamous cell head and neck cancer (SCHNC). Head and Neck 16:520, 1994 (Abstr).
116. [116] Adelstein DJ, Kalish LA, Adams GL, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 11:2136-2142, 1993.
117. [117] Dobrowsky W, Dobrowsky E, Strassl H, Braun O, Gritzmann N, Scheiber V. Combined modality treatment of advanced cancers of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 20:239-242, 1991.
118. [118] Wendt TG, Hartenstein RC, Wustrow TPU, Lissner J. Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: A phase II study. J Clin Oncol 7:471-476, 1989.
119. [119] Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol 14:419-426, 1991.
120. [120] Vokes EE, Haraf DJ, Mick R, et al. Concomitant chemoradiotherapy for intermediate stage head and neck cancer (HNC). Proc ASCO 13:282, 1994 (Abstr).
121. [121] Vokes EE, Weichselbaum RR, Mick R, McEvilly JM, Haraf DJ, Panje WR. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:877-882, 1992.
122. [122] Keane TJ, Cummings BJ, O'Sullivan B, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin-C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 25:613-618, 1993.
123. [123] Weissler MC, Melin S, Sailer SL, Qaqish BF, Rosenman JG, Pillsburg HC. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 118:806-810, 1992.
124. [124] Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12:385-395, 1994.
125. [125] Adelstein DJ, Sharan VM, Earle AS, et al. Long-term followup of a prospective randomized trial comparing simultaneous and sequential chemoradiotherapy for squamous cell head and neck cancer. In: Salmon SE, ed., Adjuvant Therapy of Cancer VII. Philadelphia: J.B. Lippincott, 1993; 82-91.
126. [126] Adelstein DJ, Lavertu P, Saxton JP, et al. Concurrent combination chemotherapy (CT) and continuous course radiotherapy (RT) for squamous cell head and neck cancer (SCHNC): Toxicity and results. Head and Neck 16:490, 1994 (Abstr).
127. [127] Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60:1178-1183, 1987.
128. [128] Viani L, Stell PM, Dalbe JE. Recurrence after radiotherapy for glottic carcinoma. Cancer 67:577-584, 1991.
129. [129] Davidson MJ, Briant TD, Gullane PJ, et al. The role of surgery following radiotherapy failure for advanced laryngopharyngeal cancer: A prospective study. Proc 3rd Int Conf Head and Neck Cancer, San Francisco, CA, July 26-30, 1992; p. 97 (Abstr).
130. [130] Popkin J, Hong WK, Dorman B, et al. Voice preservation with sequential chemotherapy and radiation therapy without laryngectomy in patients with operable stage III, IV squamous cell carcinoma of the larynx and hypopharynx. Proc ASCO 4:149, 1985 (Abstr).
131. [131] Pfister DG, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 9:850-859, 1991.
132. [132] Price LA, Shaw HJ, Hill BT. Larynx preservation after initial non-cisplatin containing combination chemotherapy plus radiotherapy, as opposed to surgical intervention with or without radiotherapy in previously untreated advanced head and neck cancer: Final analysis after 12 years follow-up. J Laryngol Otol 107:211-216, 1993.
133. [133] Karp DD, Vaughan CW, Carter R, et al. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. Am J Clin Oncol 14:273-279, 1991.
134. [134] Demard F, Chauvel P, Santini J, Vallicioni J, Thyss A, Schneider M. Response to chemotherapy as justification for modification of the therapeutic strategy for pharyngolaryngeal carcinomas. Head and Neck 12:225-231, 1990.
135. [135] Wolf G, Hong W, Fisher, et al. Larynx preservation with induction chemotherapy (CT) and radiation (XRT) in advanced laryngeal cancer: Final results of the VA Laryngeal Cancer Study Group cooperative trial. Proc ASCO 12:277, 1993 (Abstr).
136. [136] Tannock IF, Cummings BJ. Neoadjuvant chemotherapy in head and neck cancer: No way to preserve a larynx. J Clin Oncol 10:343, 1992.
137. [137] Shirinian MH, Weber RS, Lippman SM, et al. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M.D. Anderson Cancer Center experience. Head and Neck 16:39-44, 1994.
138. [138] Pinto HA, Goffinet DR, Fee WE. Induction chemotherapy followed by simultaneous chemoradiotherapy (CRT) for organ preservation in advanced resectable head and neck cancer. Proc ASCO 13:280, 1994 (Abstr).
139. [139] Urba SG, Wolf GT, Forastiere AA, Esclamado M, McLaughlin W, Thornton AF. Organ preservation at specific non-laryngeal sites of advanced head and neck cancer (H and N CA). Head and Neck 16:489, 1994 (Abstr).
140. [140] Lefebvre JL, Sahmoud T. Larynx preservation in hypopharynx squamous cell carcinoma: Preliminary results of a randomized study (EORTC 24891). Proc ASCO 13:283, 1994 (Abstr).
141. [141] Adelstein DJ, Sharan VM, Earle AS, et al. Surgical modification or elimination after chemoradiotherapy for locally confined squamous cell head and neck cancer. Head and Neck Oncology Research. Proc 2nd Int Head and Neck Oncology Research Conference, Arlington, VA, USA, September 10-12, 1987; 253-259.
142. [142] Hirsch SM, Caldarelli DD, Hutchinson JC, et al. Concomitant chemotherapy and split-course radiation for cure and preservation of speech and swallowing in head and neck cancer. Laryngoscope 101:583-586, 1991.
143. [143] Turgman J, Modan B, Shilon M, Rappaport Y, Shanon E. Nasopharyngeal cancer in a total population: Selected clinical and epidemiological aspects. Br J Cancer 36: 783-786, 1977
144. [144] Baker SR, Wolfe RA. Prognostic factors in nasopharyngeal malignancy. Cancer 49:163-169, 1982
145. [145] Dickson RI, Flores AD. Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971-1980. Laryngoscope 95:276-283, 1985.
146. [146] Vickram B, Mishra UB, Strong EW, Manolatos S. Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys 11:1455-1459, 1985.
147. [147] Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: A study of 256 male patients. J Surg Oncol 33:194-197, 1986.
148. [148] Rahima M, Rakowsky E, Barzilay J, Sidi J. Carcinoma of the Nasopharynx: an analysis of 91 cases and a comparison of differing treatment approaches. Cancer 58:843-849, 1986.
149. [149] Bentzen JKD, Ockelmann HH, Albeck H, Olsen J, Hansen HS. Nasopharyngeal carcinoma treated at the Finsen Institute, Copenhagen 1965-1985: Survival and some prognostic factors. Laryngoscope 101:635-642, 1991.
150. [150] Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: Factors affecting prognosis. Int J Radiat Oncol Biol Phys 23:271-280, 1992.
151. [151] Kaasa S, Kragh-Jensen E, Bjordal K, et al. Prognostic factors in patients with nasopharyngeal carcinoma. Acta Oncol 32:531-536, 1993.
152. [152] Menakanit W, Muir CS, Jain DK. Cancer in Chiang Mai, north Thailand. A relative frequency study. Br J Cancer 25:225-236, 1971.
153. [153] Hsu MM, Huang SC, Lynn TC, et al. The survival of patients with nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 90:289-295, 1982.
154. [154] Zhang EP, Lian PG, Cai KL, et al. Radiation therapy of nasopharyngeal carcinoma: Prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys 16:301-305, 1989.
155. [155] Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23:261-270, 1992.
156. [156] Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1-7, 1976.
157. [157] Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36:545-547, 1985.
158. [158] Neel HB, Pearson GR, Weiland LH. Taylor WF, Goepfert HH. Immunologic detection of occult primary cancer of the head and neck. Otolaryngol Head Neck Surg 89:230-234, 1981.
159. [159] Henle W, Ho JHC, Henle G, Chau JC, Kwan HC. Nasopharyngeal carcinoma: Significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer 20:663-672, 1977.
160. [160] Neel HB, Pearson GR, Weiland LH, et al. Anti-EBV serologic tests for nasopharyngeal carcinoma. Laryngoscope 90:1981-1990, 1980.
161. [161] Neel HB, Pearson GR, Weiland LH, et al. Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 91:255-262, 1983.
162. [162] Neel HB, Taylor WF. New staging system for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 115:1293-1303, 1989.
163. [163] de-Vathaire F, Sancho-Garnier H, De-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 42:176-181, 1988.
164. [164] Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 29:139-141, 1982.
165. [165] Zong YS, Sham JST, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69:3-7, 1992.
166. [166] Cooper JS, Scott C, Marcial V, et al. The relationship of nasopharyngeal carcinomas and second independent malignancies based on the Radiation Therapy Oncology Group experience. Cancer 67:1673-1677, 1991
167. [167] Ho JHC, Huang DP, Fong YY. Salted fish and nasopharyngeal carcinoma in southern Chinese. Lancet 2:626, 1978.
168. [168] Armstrong W, Armstrong MJ, Yu MC, Henderson BE. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res 43:2967-2970, 1983.
169. [169] Yu MC, Ho JHC, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: Report of a case-control study in Hong Kong. Cancer Res 46:956-961, 1986.
170. [170] Yu MC, Mo CC, Chong WX, Yeh FS, Henderson BE. Preserved foods and nasopharyngeal carcinoma: A case-control study in Guangxi, China. Cancer Res 48:1954-1959, 1988.
171. [171] Simons MJ, Wee GB, Day NE, Morris PJ, Shanmugaratnam K, De-The GB. Immunogenetic aspects of nasopharyngeal carcinoma: I. Differences in HL-A antigen profiles between patients and control groups. Int J Cancer 13:122-134, 1974.
172. [172] Simons MJ, Wee GB, Chan SH, Shanmugaratnam K. Probable identification of an HL-A second-locus antigen associated with a high risk of nasopharyngeal carcinoma. Lancet 1:142-143, 1975.
173. [173] Simons MJ, Wee GB, Goh EH, et al. Immunogenetic aspects of nasopharyngeal carcinoma: IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J Natl Cancer Inst 57:977-980, 1976.
174. [174] Lu SJ, Day NE, Degos L, et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346:470-471, 1990.
175. [175] Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res 34:1189-1191, 1974.
176. [176] Buell P. Race and place in the etiology of nasopharyngeal cancer: A study based on California death certificates. Int J Cancer 11:268-272, 1973.
177. [177] Liebowitz D. Nasopharyngeal carcinoma: The Epstein-Barr virus association. Sem Oncol 21:376-381, 1994.
178. [178] Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29:1446-1449, 1972.
179. [179] O'Brien PH, Carlson R, Steubner EA, Staley CT. Distant metastases in epidermoid cell carcinoma of the head and neck. Cancer 27:304-307, 1971.
180. [180] Probert JC, Thompson RW, Bagshaw MA. Patterns of spread of distant metastases in head and neck cancer. Cancer 33:127-133, 1974.
181. [181] Khor TH, Tan BC, Chua EJ, Chia KB. Distant metastases in nasopharyngeal carcinoma. Clin Radiol 29:27-30, 1978.
182. [182] Huang SC, Lui LT, Lynn TC. Nasopharyngeal cancer: Study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys 11:1789-1793, 1985.
183. [183] Teo P, Leung SF, Yu P, Lee WY, Shiu W. A retrospective comparison between different stage classifications for nasopharyngeal carcinoma. Br J Radiol 64:901-908, 1991.
184. [184] Shiu WCT, Tsao SY. Etoposide (VP16-213) in the treatment of advanced nasopharyngeal carcinoma. Eur J Clin Oncol 24:797-798, 1988.
185. [185] Hu OY, Chang SP, Jame JM, et al. Pharmacokinetic and pharmacodynamic studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 24:332-337, 1989.
186. [186] Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. Cancer 68:2120-2124, 1991.
187. [187] Dugan M, Choy D, Ngai A, et al. Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncol7 ogy Association Group Study. J Clin Oncol 11:70-76, 1993.
188. [188] Decker DA, Drelichman A, Al-Sarraf M, Crissman J, Reed ML. Chemotherapy for nasopharyngeal carcinoma: A ten year experience. Cancer 52:602-605, 1983.
189. [189] Boussen H, Cvitkovic E, Wendling JL, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 9:1675-1681, 1991.
190. [190] Orecchia R, Airoldi M, Sola B, et al. Results of chemotherapy plus external reirradiation in the treatment of locally advanced recurrences of nasopharyngeal carcinoma. Oral Oncol, Eur J Cancer 28B:109-111, 1992.
191. [191] Gebbia V, Zerillo G, Restivo G, et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: A retrospective analysis of 40 cases. Br J Cancer 68:191-194, 1993.
192. [192] Chi KH, Chan WK, Cooper DL. Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer 73:247-252, 1994.
193. [193] Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 5:87-89, 1994.
194. [194] Mahjoubi R, Azli N, Bachouchi M, et al. Metastatic undifferentiated carcinoma of nasopharyngeal type treated with bleomycin, epirubicin, and cisplatin (BEC). Final report. Proc ASCO 11:240, 1992 (Abstr).
195. [195] McNeese MD, Fletcher GH. Retreatment of recurrent nasopharyngeal carcinoma. Radiology 138:191-193, 1981.
196. [196] Yan JH, Hu YH, Gu XZ. Radiation therapy of recurrent nasopharyngeal carcinoma. Acta Radiol 22:23-28, 1983.
197. [197] Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma. Treatment techniques and results. Int J Radiat Oncol Biol Phys 13:953-956, 1987.
198. [198] Chen WZ, Zhou DL, Luo KS. Long-term observation after radiotherapy for nasopharyngeal carcinoma (NPC). Int J Radiat Oncol Biol Phys 16:311-314, 1989.
199. [199] Pryzant RM, Wendt CD, Delclos L, Peters LJ. Re-treatment of nasopharyngeal carcinoma in 53 patients. Int J Radiat Oncol Biol Phys 22:941-947, 1992.
200. [200] Tannock I, Payne D, Cummings B, et al. Sequential chemotherapy and radiation for nasopharyngeal cancer: Absence of long-term benefit despite a high rate of tumor response to chemotherapy. J Clin Oncol 5:629-634, 1987.
201. [201] Dimery IW, Legha SS, Peters LJ, Goepfert H, Oswald MJ. Adjuvant chemotherapy for advanced nasopharyngeal carcinoma. Cancer 60:943-949, 1987.
202. [202] Clark JR, Norris CM, Dreyfuss AI, et al. Nasopharyngeal carcinoma: The Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy and radiotherapy. Ann Otol Rhinol Laryngol 96:608-614, 1987.
203. [203] Al-Kourainy K, Crissman J, Ensley J, Kish J, Kelly, J, Al-Sarraf M. Excellent response to cis-platinum based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol 11:427-430, 1988.
204. [204] Atichartakarn V, Kraiphibul P, Clongsusuek P, Pochanugool L, Kulapaditharom B, Ratanatharathorn V. Nasopharyngeal carcinoma: Result of treatment with cis-diamminedichloroplatinum II, 5-fluorouracil, and radiation therapy. Int J Radiat Oncol Biol Phys 14:461-469, 1988.
205. [205] Bachouchi M, Cvitkovic E, Azli N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin and cisplatin before radiotherapy. J Natl Cancer Inst 82:616-620, 1990.
206. [206] Kraiphibul P, Clongsusek P, Ratanatharathorn V, Atichartakarn V, Kulapaditharom B, Isarangkul W. Nasopharyngeal carcinoma: Results of treatment by radiotherapy vs chemotherapy plus radiotherapy. J Med Assoc Thai 74:391-396, 1991.
207. [207] Fountzilas G, Daniilidis J, Kosmidis P, et al. Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer: A retrospective analysis of 39 cases. Acta Oncol 30:831-834, 1991.
208. [208] Azli N, Armand JP, Rahal M, et al. Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. Eur J Cancer 28A: 1792-1797, 1992.
209. [209] Hill BT, Price LA, MacRae K. Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous cell carcinomas of the head and neck treated with initial combination chemotherapy without cisplatin. J Clin Oncol 4:1340-1347, 1986.
210. [210] Fandi A, Gueddari E, Benhamou E, et al. Neoadjuvant chemotherapy with epirubicin, cisplatin, bleomycin (BEC) in undifferentiated nasopharyngeal cancer (UCNT): Preliminary results of an international phase III trial. Fourth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, Sept 8-11, 1994 (Abstr).
211. [211] Souhami L, Rabinowits M. Combined treatment in carcinoma of the nasopharynx. Laryngoscope 98:881-883, 1988.
212. [212] Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic, Ager PJ. Chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A Radiation Therapy Oncology Group Study. J Clin Oncol 8:1342-1351, 1990.
213. [213] Tsujii H, Kamada T, Tsuji H, et al. Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy. Cancer 63:1668-1672, 1989.
214. [214] Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. J Clin Oncol 6:1401-1410, 1988.
215. [215] Al-Sarraf M, LeBlanc M, Giri PGS, et al. Superiority of chemo-radiotherapy vs. radiotherapy in patients with locally advanced nasopharyngeal cancer. Preliminary results of Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc ASCO 15:313, 1996 (Abstr).